MARIA FINCH: Open Payments
NPI 1376916296 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,627 in 81 payments from 24 companies in 2025. Trend: 2023 $1,116 · 2024 $2,789 · 2025 $1,627
Food & beverage: $1,567Education: $60
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 16 | $224 |
| AstraZeneca Pharmaceuticals LP | 11 | $218 |
| Regeneron Healthcare Solutions, Inc. | 10 | $204 |
| GENZYME CORPORATION | 6 | $135 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $94 |
| United Therapeutics Corporation | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| SANOFI-AVENTIS U.S. LLC | 1 | $60 |
| Viatris Specialty LLC | 3 | $56 |
| Verona Pharma, Inc. | 3 | $55 |
Products named: DUPIXENT, NUCALA, FASENRA, Tyvaso, TEZSPIRE, GLASSIA, YUPELRI, Ohtuvayre.
Industry payments across NC — which companies pay providers there.
